微小残存病変検査の世界市場は、2023年の22億ドルから 2028年までに 43億ドルに達し、2023 年から2028年までのCAGRは14.3%になると推定されます。
目次
Chapter- 1: Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Research Methodology
Information Sources
Geographic Breakdown
Chapter- 2: Summary and Highlights
Market Outlook
Chapter- 3: Market Overview
Definition of Minimal Residual Disease
Chapter- 4: Market Dynamics
Market Dynamics
Impact of Covid-19 on Minimal Residual Disease Testing Market
Regulatory Landscape
Chapter- 5: Global Minimal Residual Disease Testing Market by Technology
Overview
Flow Cytometry
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Others
Chapter- 6: Global Minimal Residual Disease Testing Market by Application
Overview
Hematological Malignancies
Solid Tumors
Others
Chapter- 7: Global Minimal Residual Disease Testing Market by Region
North America
Europe
Asia-Pacific
Rest of the World
Table 21 : Global Market for Minimal Residual Disease Testing, by Region, Through 2028
Figure 20 : Global Market for Minimal Residual Disease Testing, by Region, 2021-2028
Chapter- 8: ESG Developments
Importance of ESG in Minimal Residual Disease Testing Industry
ESG Ratings and Metrics: Understanding the Data
ESG Practices in the Minimal Residual Disease Testing Industry
Future Trends
BCC Research Viewpoint
Chapter- 9: Emerging Technologies and Developments
Emerging Technologies
Chapter- 10: M&A Analysis
M&A Analysis
Chapter- 11: Competitive Intelligence
Top Market Players Ranking, 2022
Key Strategies Adopted by Companies
Chapter- 12: Company Profiles
ADAPTIVE BIOTECHNOLOGIES CORP.
AMGEN INC.
ASTRAZENECA PLC
BIO-RAD LABORATORIES INC.
CERGENTIS B.V.
EXACT SCIENCES CORP.
GUARDANT HEALTH INC.
ILLUMINA INC. (GRAIL LLC)
INVITAE
INVIVOSCRIBE INC.
NATERA INC.
NEOGENOMICS INC.
QIAGEN
SYSMEX CORP.
